BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26568589)

  • 1. Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
    Steiman AJ; Gladman DD; Ibañez D; Noamani B; Landolt-Marticorena C; Urowitz MB; Wither JE
    J Rheumatol; 2015 Dec; 42(12):2318-26. PubMed ID: 26568589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
    Steiman AJ; Urowitz MB; Ibañez D; Li TT; Gladman DD; Wither J
    J Rheumatol; 2015 May; 42(5):810-6. PubMed ID: 25729033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study.
    Huang H; Mu L; Zhang Z; Gao D; Hao Y; Zhou W
    Arthritis Res Ther; 2021 Oct; 23(1):275. PubMed ID: 34715915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.
    Steiman AJ; Gladman DD; Ibañez D; Urowitz MB
    Arthritis Care Res (Hoboken); 2012 Apr; 64(4):511-8. PubMed ID: 22162433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome.
    Steiman AJ; Gladman DD; Ibañez D; Urowitz MB
    J Rheumatol; 2010 Sep; 37(9):1822-7. PubMed ID: 20595281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.
    Ng KP; Manson JJ; Rahman A; Isenberg DA
    Arthritis Rheum; 2006 Dec; 55(6):900-4. PubMed ID: 17139667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares.
    Walz LeBlanc BA; Gladman DD; Urowitz MB
    J Rheumatol; 1994 Dec; 21(12):2239-41. PubMed ID: 7699623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired phagocytosis of apoptotic cell material in serologically active clinically quiescent patients with systemic lupus erythematosis.
    Huang WN; Tso TK; Wu HC; Yang HF; Tsay GJ
    Int J Rheum Dis; 2016 Dec; 19(12):1310-1316. PubMed ID: 26692544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up and management of serologically active clinically quiescent cases in pediatric systemic lupus erythematosus.
    Capone G; Lojacono C; Al-Bayitee F; Makvandi S; Hennon T; Wrotniak B; Abdul-Aziz R
    Reumatologia; 2021; 59(4):244-251. PubMed ID: 34538955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically active serologically quiescent systemic lupus erythematosus.
    Gladman DD; Hirani N; Ibañez D; Urowitz MB
    J Rheumatol; 2003 Sep; 30(9):1960-2. PubMed ID: 12966598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
    Rose T; Grützkau A; Hirseland H; Huscher D; Dähnrich C; Dzionek A; Ozimkowski T; Schlumberger W; Enghard P; Radbruch A; Riemekasten G; Burmester GR; Hiepe F; Biesen R
    Ann Rheum Dis; 2013 Oct; 72(10):1639-45. PubMed ID: 23117242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.
    Landolt-Marticorena C; Bonventi G; Lubovich A; Ferguson C; Unnithan T; Su J; Gladman DD; Urowitz M; Fortin PR; Wither J
    Ann Rheum Dis; 2009 Sep; 68(9):1440-6. PubMed ID: 18772188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
    Conti F; Ceccarelli F; Perricone C; Miranda F; Truglia S; Massaro L; Pacucci VA; Conti V; Bartosiewicz I; Spinelli FR; Alessandri C; Valesini G
    PLoS One; 2012; 7(9):e45934. PubMed ID: 23029327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
    Bilgic H; Ytterberg SR; Amin S; McNallan KT; Wilson JC; Koeuth T; Ellingson S; Newman B; Bauer JW; Peterson EJ; Baechler EC; Reed AM
    Arthritis Rheum; 2009 Nov; 60(11):3436-46. PubMed ID: 19877033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines in relation to autoantibodies before onset of symptoms for systemic lupus erythematosus.
    Eriksson C; Rantapää-Dahlqvist S
    Lupus; 2014 Jun; 23(7):691-6. PubMed ID: 24531079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus.
    Ferreira GA; Teixeira AL; Sato EI
    Lupus; 2010 Jul; 19(8):927-34. PubMed ID: 20410153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus.
    Miyawaki Y; Sada K; Asano Y; Hayashi K; Yamamura Y; Hiramatsu S; Ohashi K; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
    Lupus; 2018 Nov; 27(13):2093-2100. PubMed ID: 30309286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity.
    Wu Q; Yang Q; Lourenco E; Sun H; Zhang Y
    Arthritis Res Ther; 2011 Jun; 13(3):R88. PubMed ID: 21679442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.